参考文献/References:
[1] Tsao CW,Aday AW,Almarzooq ZI,et al. Heart Disease and Stroke Statistics—2022 Update:a report from the American Heart Association[J]. Circulation,2022,145(8):e153-e639.
[2] Global Burden Of Disease Study,Institute For Health Metrics and Evaluation[EB/OL]. [2021-08-01].http://ghdx.health-data.org/.
[3] Du X,Guo L,Xia S,et al. Atrial fibrillation prevalence,awareness and management in a nationwide survey of adults in China[J]. Heart,2021,107(7):535-541.
[4] Hindricks G,Potpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery(EACTS):the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology(ESC) Developed with the special contribution of the European Heart Rhythm Association(EHRA) of the ESC[J]. Eur Heart J,2021,42(5):373-498.
[5] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志,2022,37(6):553-578.
[6] 中华医学会心电生理和起搏分会,中国医师协会心律学专业委员会,中国房颤中心联盟心房颤动防治专家工作委员会. 心房颤动：目前的认识和治疗建议(2021)[J]. 中华心律失常学杂志,2022,26(1):15-88.
[7] Chamberlain AM,Alonso A,Gersh BJ,et al. Multimorbidity and the risk of hospitalization and death in atrial fibrillation:a population-based study[J]. Am Heart J,2017,185:74-84.
[8] Jaspers Focks J,Brouwer MA,Wojdyla DM,et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation:post hoc analysis of the ARISTOTLE trial[J]. BMJ,2016,353:i2868.
[9] Wang J,Yang Y,Zhu J,et al. Multimorbidity and polypharmacy in Chinese emergency department patients with atrial fibrillation and impacts on clinical outcomes[J]. Front Cardiovasc Med,2022,9:806234.
[10] Kotalczyk A,Guo Y,Wang Y,et al. Impact of multimorbidity and polypharmacy on clinical outcomes of elderly Chinese patients with atrial fibrillation[J]. J Clin Med,2022,11(5):1370.
[11] Guo Y,Tian Y,Wang H,et al. Prevalence,incidence,and lifetime risk of atrial fibrillation in China:new insights into the global burden of atrial fibrillation[J]. Chest,2015,147(1):109-119.
[12] Rasmussen PV,Pallisgaard JL,Hansen ML,et al. Treatment of older patients with atrial fibrillation by morbidity burden[J]. Eur Heart J Qual Care Clin Outcomes,2022,8(1):23-30.
[13] Woo B,Tam W,Rangpa T,et al. A Nurse-Led Integrated Chronic Care E-enhanced Atrial Fibrillation(NICE-AF) clinic in the community:a preliminary evaluation[J]. Int J Environ Res Public Health,2022,19(8):4467.
[14] Ritchie LA,Lip GYH,Lane DA. Optimization of atrial fibrillation care:management strategies and quality measures[J]. Eur Heart J Qual Care Clin O utcomes,2021,7(2):121-133.
[15] Hsieh HL,Kao CW,Cheng SM,et al. A web-based integrated management program for improving medication adherence and quality of life,and reducing readmission in patients with atrial fibrillation:randomized controlled trial[J]. J Med Internet Res,2021,23(9):e30107.
[16] Ali-Ahmed F,Pieper K,North R,et al. Shared decision-making in atrial fibrillation:patient-reported involvement in treatment decisions[J]. Eur Heart J Qual Care Clin Outcomes,2020,6(4):263-272.
[17] Hendriks J,Tieleman RG,Vrijhoef H,et al. Integrated specialized atrial fibrillation clinics reduce all-cause mortality:post hoc analysis of a randomized clinical trial[J]. Europace,2019,21(12):1785-1792.
[18] Lip GYH. The ABC pathway:an integrated approach to improve AF management[J]. Nat Rev Cardiol,2017,14(11):627-628.
[19] Chao T,Joung B,Takahashi Y,et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation:executive summary[J]. Thromb Haemost,2022,122(1):20-47.
[20] Guo Y,Imberti JF,Kotalczyk A,et al. 4S-AF scheme and ABC pathway guided management improves outcomes in atrial fibrillation patients[J]. Eur J Clin Invest,2022,52(6):e13751.
[21] Romiti GF,Pastori D,Rivera-Caravaca JM,et al. Adherence to the ‘Atrial fibrillation Better Care’ pathway in p atients with atrial fibrillation:impact on c linical outcomes—A systematic review and meta-analysis of 285,000 patients[J]. Thromb Haemost,2022,122(3):406-414.
[22] Stevens D,Harrison SL,Kolamunnage-Dona R,et al. The Atrial Fibrillation Better Care pathway for managing atrial fibrillation:a review[J]. Europace,2021,23(10):1511-1527.
[23] Proietti M,Romiti GF,Olshansky B,et al. Comprehensive management with the ABC(Atrial fibrillation Better Care) pathway in clinically c omplex patients with atrial fibrillation:a post hoc ancillary analysis from the AFFIRM trial[J]. J Am Heart Assoc,2020,9(10):e14932.
[24] Kotalczyk A,Guo Y,Stefil M,et al. Effects of the Atrial fibrillation Better Care pathway on outcomes among clinically complex Chinese patients with atrial fibrillation with multimorbidity and polypharmacy:a report from the ChiOTEAF Registry[J]. J Am Heart Assoc,2022,11(7):e24319.
[25] Proietti M,Lip G,Laroche C,et al. Relation of outcomes to ABC(Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation:an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term(AFGen LT) Registry[J]. Europace,2021,23(2):174-183.
[26] Guo Y,Imberti JF,Kotalczyk A,et al. Atrial fibrillation Better Care pathway adherent care improves outcomes in Chinese patients with atrial fibrillation[J]. JACC Asia,2022.DOI:10.1016/j.jacasi.2022.01.007.
[27] Pastori D,Farcomeni A,Pignatelli P,et al. ABC(Atrial fibrillation Better Care) pathway and healthcare costs in atrial fibrillation:the ATHERO-AF study[J]. Am J Med,2019,132(7):856-861.
[28] Potpara TS,Mihajlovic M,Zec N,et al. Self-reported treatment burden in patients with atrial fibrillation:quantification,major determinants,and implications for integrated holistic management of the arrhythmia[J]. Europace,2020,22(12):1788-1797.
[29] Sandhu RK,Seiler A,Johnson CJ,et al. Heart Rhythm Society Atrial Fibrillation Centers of Excellence Study:a survey analysis of stakeholder practices,needs,and barriers[J]. Heart Rhythm,2022,19(6):1039-1048.
[30] Khurshid S,Friedman S,Reeder C,et al. ECG-based deep learning and clinical risk factors to predict atrial fibrillation[J]. Circulation,2022,145(2):122-133.
[31] Schwab K,Nguyen D,Ungab G,et al. Artificial intelligence MacHIne learning for the detection and treatment of atrial fibrillation guidelines in the emergency department setting(AIM HIGHER):assessing a machine learning clinical decision support tool to detect and treat non-valvular atrial fibrillation in the emergency department[J]. J Am Coll Emerg Physicians Open,2021,2(4):e12534.
[32] Guo Y,Lane DA,Wang L,et al. Mobile health technology to improve care for patients with atrial fibrillation[J]. J Am Coll Cardiol,2020,75(13):1523-1534.
[33] Guo Y,Guo J,Shi X,et al. Mobile health technology-supported atrial fibrillation screening and integrated care:a report from the mAFA-Ⅱtrial long-term extension cohort[J]. Eur J Intern Med,2020,82:105-111.
[34] Yao Y,Guo Y,Lip GYH,et al. The effects of implementing a mobile health–Technology Supported Pathway on Atrial Fibrillation–Related adverse events among patients with multimorbidity:the mAFA-Ⅱrandomized clinical trial[J]. JAMA Netw Open,2021,4(12):e2140071.
[35] Luo X,Xu W,Ming W,et al. Cost-effectiveness of mobile health-based integrated care for atrial fibrillation:model development and data analysis[J]. J Med Internet Res,2022,24(4):e29408.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(3):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(3):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(3):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(3):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(3):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(3):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]